09.30 – 13.00
Business meeting of the acute leukemia working party
13.45
6th IPC Symposium: welcome introductions.
D. Blaise & M. Mohty
14.00
SESSION 1
Worldwine trends for allogeneic and car t-cells
Chair: M. Mohty
14.00
Chinese perspective.
X. J. Huang
14.20
European perspective.
A. Sureda
14.40
US perspective.
B. Savani
15.00
Impact of Covid pandemic on cellular therapy.
C. Chabannon
15.20
Questions & answers
15.40
Coffee break & exhibition visit
16.00
Keynote lecture
Chair: D. Blaise
16.00
PTCY 20 years later: what a journey!
L. Luznik
16.30
Car-T cells: already 10 years!
M. Mohty
17.00
Questions & answers
17.20
SESSION 2
Solved or unsolved issues in HSCT?
Chair: R. Devillie
17.20
The best donor in haplo HSCT?
S. Fürst
17.40
MAC or RIC?
A. Nagler
18.00
BM or PBSC?
A. Bazarbachi
18.20
Novel alkylating agents in conditioning.
D. Blaise
18.40
Questions & answers
19.00
Christian Cailliot Award
19.15
End of sessions
20.30
Congress dinner
13.30
SESSION 3
Old issues and new perspectives
Chair: N-C. Gorin
10.30
New reduce toxicity conditioning of melphalan-busulfan and fludarabine in patients with AML/MDS
J. Hu
10.50
The place of fecal microbiota in HSCT.
F. Malard
11.10
Immmunotherapy with NK cells.
R. Devillier
11.30
What could be the next utility for cord blood?
S. Parmar
11.50
Questions & answers
12.10
Lunch & exhibition visit
13.00
SESSION 4
Personalized medecine
Chair: S. Fürst
13.00
How to personalize CDT in haemoglobinopathies transplant?
B. Andersson
13.20
Dose adapted drugs for CDT.
J. Boelens
13.40
HSCT personalized approach in older patients.
S. Harbi
14.00
Questions & answers
14.20
SESSION 5
Geneticallly modified cells (part 1)
Chair: F. Malard
14.20
Relapse prevention post Car-T cells treatment: Allo HSCT?
H. Huang
14.40
Relapse after post Car-T cells treatment: second infusion?
J. Gauthier
15.00
Car T-cells or bispecific MoABs for all?
E. Brissot
15.20
Multiple myeloma: the next challenge?
I. Yakoub-Agha
15.40
Questions & answers
16.00
Coffee break & exhibition visit
16.20
SESSION 6
Generically modified cells (part 2)
Chair: I. Yakoub-Agha
16.20
Point of care strategy for Car-T cells: a valid option?
A. Urbano-Ispizua
16.40
The evolution of the COVID-19 pandemic in a US hematological malignancy and cell therapy unit: from prevention to infection to vaccination.
F. B. Petersen
17.00
Cellular immunotherapy in low-income countries: myth or reality?
R. Gabus
17.20
Questions & answers
17.40
SESSION 7
Challenging questions
Chair: E. Brissot
17.40
Relapse prediction after mismatch transplant.
L. Vago
18.00
Post transplant treatments: for which patients?
I. Gojo
18.20
How can we use MRD assessments before
allo-SCT in acute myeloid leukemia?
N. Vey
18.40
Allogeneic HSCT for NHL at the time of Car-T cells.
L. Castagna
19.00
Questions & answers
19.20
Conclusive remarks
